Physician profile
Beatrixe Eugene
NPI 1306899240
$2,703.89
in general payments reported to CMS, 2019-2025
26 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $252 · 2021: $616 · 2022: $426 · 2023: $732 · 2024: $216 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $734.24 | 2020-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $442.70 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $290.28 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.68 | 2021-2025 | |
| Astellas Pharma US INC | $166.06 | 2023-2025 | Veozah |
| Lilly USA, LLC | $151.89 | 2020-2021 | |
| Glaxosmithkline, LLC. | $124.06 | 2023 | |
| Sanofi-Aventis U.S. LLC | $94.44 | 2020-2022 | |
| Pfizer INC. | $66.34 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $57.57 | 2021-2023 | Rexulti |
| Amarin Pharma, INC. | $55.07 | 2021 | |
| Exact Sciences Corporation | $52.23 | 2023-2024 | Cologuard Collection Kit |
| Cequr Corporation | $46.42 | 2023-2024 | Cequr Simplicity |
| Medtronic, INC. | $37.39 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $24.11 | 2023 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.85 | 2020 | |
| Roche Diabetes Care, INC. | $20.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.18 | 2021 | |
| Esperion Therapeutics, INC. | $18.27 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.85 | 2022 | |
| Abbott Laboratories | $15.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.17 | 2020 | |
| Amgen INC. | $14.26 | 2023 | Evenity, Prolia |
| Currax Pharmaceuticals LLC | $13.85 | 2020 | |
| Phadia US INC. | $13.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.73 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatrixe Eugene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.